To explore the efficacy of triflusal in patients with symptomatic peripheral microcirculation dysfunction. Triflusal is a salicylate compound approved in several countries as antithrombotic agent and it additionally has vasodilatory effect. The hypothesis is to explore if there is a improvement of peripheral microcirculation by triflusal.

Inclusion Criteria:

• Between 40 and 70 years of age
• Diagnosed vasospastic syndrome with nailfold capillaroscopy (Fingertip is subjected to carbon dioxide at -15°C for 60 seconds. People found to have a blood-flow standstill of at least 12s in one or more capillaries were defined as having vasospasticity)
• More than seven points in 10-question interview provided by Nagashima et al.
• Written informed consent

Exclusion Criteria:

• Prior documented diabetes
• Overt peripheral artery disease
• Pregnant or nursing
• bleeding tendency
• Any contraindication of antiplatelet agent
• Thrombocytopenia (platelet < 100,000mm3)
• Chronic liver disease (ALT > 100 IU/L or AST > 100 IU/L) or renal dysfunction (creatinine > 4.0 mg/dl)
• Patients who can not stop to take aspirin